English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Prostate cancer is the leading cause of solid organ malignancy in American men with over 33,330 men predicted to die of prostate cancer in 2020 by the American Cancer Society. An increase in PSA screening has led to an increased number of men being diagnosed with both clinically significant and insignificant disease. Such an increase in detection has made selecting patients who would benefit from more aggressive treatment modalities with surgery or radiation as opposed to watchful waiting more complex. Several predictive models have been developed which utilize well established diagnostic risk factors aimed to predict which patients are at highest risk of disease progression and thus require more aggressive treatment modalities i.e., radical prostatectomy (RP). This comprehensive review article will discuss how such risk stratification models along with biochemical markers and imaging modalities can be used to predict which patients may harbor pathologically aggressive prostate cancer and would benefit from surgical intervention.

Predictors of pathologically aggressive prostate cancer and surgical management